{"parse":{"title":"Hypodysfibrinogenemia","pageid":55097960,"revid":856889086,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em\"><tbody><tr><th colspan=\"2\" style=\"text-align:center;font-size:125%;font-weight:bold;background:#ccc\">Hypodysfibrinogenemia</th></tr><tr><th scope=\"row\">Synonyms</th><td>\nCongenital hypodysfibrinogenemia</td></tr></tbody></table>\n<p><b>Hypodysfibrinogenemia</b>, also termed <b>congenital hypodysfibrinogenemia</b>, is a rare hereditary <a href=\"/wiki/List_of_fibrinogen_disorders\" title=\"List of fibrinogen disorders\">fibrinogen disorder</a> cause by mutations in one or more of the genes that encode a factor critical for <a href=\"/wiki/Blood_clotting\" class=\"mw-redirect\" title=\"Blood clotting\">blood clotting</a>, <a href=\"/wiki/Fibrinogen\" title=\"Fibrinogen\">fibrinogen</a>. These mutations result in the production and circulation at reduced levels of fibrinogen at least some of which is dysfunctional.<sup id=\"cite_ref-pmid28211264_1-0\" class=\"reference\"><a href=\"#cite_note-pmid28211264-1\">&#91;1&#93;</a></sup>  Hypodysfibrinogenemia exhibits <a href=\"/wiki/Penetrance#Degrees_of_penetrance\" title=\"Penetrance\">reduced penetrance</a>, i.e. only some family members with the mutated gene develop symptoms.<sup id=\"cite_ref-pmid27019462_2-0\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid28550239_3-0\" class=\"reference\"><a href=\"#cite_note-pmid28550239-3\">&#91;3&#93;</a></sup>\n</p><p>The disorder is similar to a form of <a href=\"/wiki/Dysfibrinogenemia\" title=\"Dysfibrinogenemia\">dysfibrinogenemia</a> termed congenital dysfibrinogenemia. However, congenital dysfibrinogenemia differs form hypodysfibrinogenemia in four ways. Congenital dysfibrinogenemia involves: the circulation at normal levels of fibrinogen at least some of which is dysfunctional; a different set of causative gene mutations; a somewhat different mix of clinical symptoms; and a much lower rate of penetrance.<sup id=\"cite_ref-pmid27019462_2-1\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid28550239_3-1\" class=\"reference\"><a href=\"#cite_note-pmid28550239-3\">&#91;3&#93;</a></sup>\n</p><p>Hypodysfibrinogenemia causes episodes of pathological bleeding and thrombosis due not only to low levels of circulating fibrinogen but also to the dysfunction of a portion of the circulating fibrinogen. The disorder can lead to very significant bleeding during even minor surgical procedures and women afflicted with the disorderoften suffer significant bleeding during and after giving child birth, higher rates of miscarriages, and <a href=\"/wiki/Menorrhagia\" class=\"mw-redirect\" title=\"Menorrhagia\">menorrhagia</a>, i.e. <a href=\"/wiki/Abnormal_uterine_bleeding\" title=\"Abnormal uterine bleeding\">abnormally heavy bleeding</a> during the <a href=\"/wiki/Menstruation\" title=\"Menstruation\">menstrual period</a>.<sup id=\"cite_ref-pmid28211264_1-1\" class=\"reference\"><a href=\"#cite_note-pmid28211264-1\">&#91;1&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Presentation\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Presentation</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Fibrinogen\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Fibrinogen</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Pathophysiology\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Pathophysiology</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Diagnosis\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Diagnosis</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Treatment\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Treatment</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#References\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Presentation\">Presentation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hypodysfibrinogenemia&amp;action=edit&amp;section=1\" title=\"Edit section: Presentation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In of study of 32 individuals diagnoses with hypodysfibrinogenemia, 41% presented with episodic bleeding, 43% presented with episodic thrombosis, and 16% were asymptomatic, being detected by abnormal blood tests.<sup id=\"cite_ref-pmid27019462_2-2\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup> Bleeding and thrombosis generally begin in adulthood with the average age at the time of presentation and diagnosis being 32 years. Bleeding is more frequent and severe in women of child-bearing age; these women may suffer miscarriages, <a href=\"/wiki/Menometrorrhagia\" title=\"Menometrorrhagia\">menometrorrhagia</a>, and excessive bleeding during child birth and/or the <a href=\"/wiki/Postpartum\" class=\"mw-redirect\" title=\"Postpartum\">postpartum</a> period. Excessive bleeding following major or minor surgery, including dental extractions, occurs in both females and males with the disorder. Thrombotic complications of the disorder are often (~50%) recurrent and can involve central and peripheral arteries, deep and superficial veins. Thrombotic events may be serious and involve occlusion of a <a href=\"/wiki/Cerebral_artery\" class=\"mw-redirect\" title=\"Cerebral artery\">cerebral artery</a> leading to <a href=\"/wiki/Stroke\" title=\"Stroke\">stroke</a>, <a href=\"/wiki/Hepatic_portal_systems\" class=\"mw-redirect\" title=\"Hepatic portal systems\">splanchnic venous thrombosis</a>, and <a href=\"/wiki/Pulmonary_thrombosis\" class=\"mw-redirect\" title=\"Pulmonary thrombosis\">pulmonary thrombosis</a> presumptively secondary to <a href=\"/wiki/Deep_vein_thrombosis\" title=\"Deep vein thrombosis\">deep vein thrombosis</a>.<sup id=\"cite_ref-pmid28211264_1-2\" class=\"reference\"><a href=\"#cite_note-pmid28211264-1\">&#91;1&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Fibrinogen\">Fibrinogen</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hypodysfibrinogenemia&amp;action=edit&amp;section=2\" title=\"Edit section: Fibrinogen\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Circulating fibrinogen is a <a href=\"/wiki/Glycoprotein\" title=\"Glycoprotein\">glycoprotein</a> made of two <a href=\"/wiki/Protein_trimer\" title=\"Protein trimer\">trimers</a> each of which is composed of three polypeptide chains, <a href=\"/wiki/Fibrinogen_alpha_chain\" title=\"Fibrinogen alpha chain\">A\u03b1</a> (also termed \u03b1) encoded by the <i>FGA</i> gene, <a href=\"/wiki/Fibrinogen_beta_chain\" title=\"Fibrinogen beta chain\">B\u03b2</a> (also termed \u03b2) encoded by the <i>FGB</i> gene, and \u03b3 encoded by the <i>FGG</i> gene. All three genes are located on the long or \"q\" arm of human chromosome 4 (at <a href=\"/wiki/Locus_(genetics)#Nomenclature\" title=\"Locus (genetics)\">positions</a> 4q31.3, 4q31.3, and 4q32.1, respectively) and are the sites where mutations occur that code for a dysfunctional fibrinogen and/or reduced fibrinogen levels which are the cause of congenital hypodysfibrinogenemia.<sup id=\"cite_ref-pmid27019463_4-0\" class=\"reference\"><a href=\"#cite_note-pmid27019463-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid27784620_5-0\" class=\"reference\"><a href=\"#cite_note-pmid27784620-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Pathophysiology\">Pathophysiology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hypodysfibrinogenemia&amp;action=edit&amp;section=3\" title=\"Edit section: Pathophysiology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Congenital hypodysfibrinogenemia is inherited as an <a href=\"/wiki/Autosomal_dominant\" class=\"mw-redirect\" title=\"Autosomal dominant\">autosomal dominant</a> disorder caused by at least 32 different types of single mutations. Ten of these mutations are in the <i>FGA</i> gene, 5 in the <i>FGB</i> gene, and 17 in the FGG gene. The mutations are mainly <a href=\"/wiki/Missense_mutations\" class=\"mw-redirect\" title=\"Missense mutations\">missense mutations</a> with <a href=\"/wiki/Nonsense_mutation\" title=\"Nonsense mutation\">nonsense</a> and <a href=\"/wiki/Frameshift_mutation\" title=\"Frameshift mutation\">Frameshift mutations</a> each occurring in 12.5% of cases.<sup id=\"cite_ref-pmid28211264_1-3\" class=\"reference\"><a href=\"#cite_note-pmid28211264-1\">&#91;1&#93;</a></sup> The causes of two fibrinogen abnormalities that characterize hypodysfibrinogenemia, i.e. circulation at reduced levels of fibrinogen at least some of which is dysfunctional, reflect different molecular mechanisms:<sup id=\"cite_ref-pmid27019463_4-1\" class=\"reference\"><a href=\"#cite_note-pmid27019463-4\">&#91;4&#93;</a></sup> \n</p>\n<ol><li>A <a href=\"/wiki/Heterozygous\" class=\"mw-redirect\" title=\"Heterozygous\">heterozygous</a> mutation in one of the two copies of either  the <i>FGA, FGB,</i> or <i>FGG</i> gene leads to production of a fibrinogen that is both dysfunctional and poorly secreted into the blood stream, e.g. fibrinogen Vlissingen, fibrinogen Philadelphia, and fibrinogen Freiburg.</li>\n<li>A <a href=\"/wiki/Homozygous\" class=\"mw-redirect\" title=\"Homozygous\">homozygous</a> mutation in both copies of one of the cited genes leads to production of a fibrinogen that is both dysfunctional and poorly secreted into the blood stream, e.g. fibrinogen Otago,  fibrinogen Marburg, and fibrinogen Sfax.</li>\n<li>Two different mutations (see <a href=\"/wiki/Compound_heterozygosity\" title=\"Compound heterozygosity\">Compound heterozygosity</a>) occur in each of the two copies of one of the cited genes, with one mutation coding for reduced formation of a functionally normal circulating fibrinogen and the second mutation coding for the circulation of a dysfunctional fibrinogen, e.g. fibrinogen Leipzig.</li>\n<li>Two different mutations occur in one copy of the cited genes, with one mutation causing hypofibrinogenemia and the other mutation coding for a dysfunctional fibrinogen, e.g. fibrinogen Keokuk.</li></ol>\n<p>The following Table adds further information on the just cited examples of hypodysfibrinogenemias. The Table gives: <b>a)</b> each mutated protein's trivial name; <b>b)</b> the gene mutated (i.e. <i>FGA, FGB,</i> or <i>FGG</i>), its mutation site (i.e. numbered nucleotide in the <a href=\"/wiki/Cloned\" class=\"mw-redirect\" title=\"Cloned\">cloned</a> gene), and name of the nucleotides (i.e. <a href=\"/wiki/Cytosine\" title=\"Cytosine\">C</a>, <a href=\"/wiki/Thymine\" title=\"Thymine\">T</a>, <a href=\"/wiki/Adenine\" title=\"Adenine\">A</a>, <a href=\"/wiki/Guanine\" title=\"Guanine\">G</a>) at these sites before&gt;after the mutation; <b>c)</b> the name of the altered fibrinogen peptide (A\u03b1, B\u03b2, or \u03bb) and the amino acids (using <a href=\"/wiki/Amino_acid#Table_of_standard_amino_acid_abbreviations_and_properties\" title=\"Amino acid\">standard abbreviations</a>) occurring before-after the mutation at the numbered amino acid(s) sites in the circulating mutated fibrinogen; <b>d)</b> the <a href=\"/wiki/Pathophysiology\" title=\"Pathophysiology\">pathophysiology</a> for the mutated fibrinogen's misfunction(s); and <b>e)</b> the clinical consequence(s) of the mutation. Unless noted as a deletion (del) or frame shift (fs), all mutations are <a href=\"/wiki/Missense_mutation\" title=\"Missense mutation\">missense</a> or <a href=\"/wiki/Nonsense_mutation\" title=\"Nonsense mutation\">nonsense mutations</a>.<sup id=\"cite_ref-pmid28211264_1-4\" class=\"reference\"><a href=\"#cite_note-pmid28211264-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid27019463_4-2\" class=\"reference\"><a href=\"#cite_note-pmid27019463-4\">&#91;4&#93;</a></sup> A <a href=\"/wiki/Nonsense_mutation\" title=\"Nonsense mutation\">nonsense mutation</a> causing a premature <a href=\"/wiki/Stop_codon\" title=\"Stop codon\">stop codon</a> and thereby a shorten polypeptide chain is notated by an X (PSC) after the altered amino acid codon.\n</p>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<th>Trivial name</th>\n<th>Gene: mutation</th>\n<th>Polypeptide chain: mutation</th>\n<th>Pathophysiology</th>\n<th>Clinical disorder\n</th></tr>\n<tr>\n<td>fibrinogen Otago</td>\n<td><i>FGA</i>: c.858_859incC</td>\n<td>A\u03b1: Arg268Gln followed by fs</td>\n<td>impaired secretion; defective <a href=\"/wiki/Polymerization\" title=\"Polymerization\">polymerization</a></td>\n<td>post-surgical and post-<a href=\"/wiki/Partum\" class=\"mw-redirect\" title=\"Partum\">partum</a> bleeding, recurrent <a href=\"/wiki/Miscariage\" class=\"mw-redirect\" title=\"Miscariage\">miscariages</a>\n</td></tr>\n<tr>\n<td>fibrinogen Marburg</td>\n<td><i>FGA</i>: c.1438A&gt;T</td>\n<td>A\u03b1: Lys461X (PSC)</td>\n<td>defective <a href=\"/wiki/Polymerization\" title=\"Polymerization\">polymerization</a></td>\n<td>post-<a href=\"/wiki/Partum\" class=\"mw-redirect\" title=\"Partum\">partum</a> bleeding, recurrent venous thrombosis\n</td></tr>\n<tr>\n<td>fibrinogen Keokuk</td>\n<td><i>FGA</i>: c.510 +1 G&gt;T; <i>FGA</i> c.1039C&gt;T (PSC)</td>\n<td>A\u03b1: <a href=\"/wiki/Splice_site_mutation\" title=\"Splice site mutation\">splice mutation</a>; A\u03b1: Gln321X (PSC)</td>\n<td>impaired fibrinogen assembly, poor fibrin clot lysis, defective polymerization</td>\n<td>recurrent venous and arterial thromboses\n</td></tr>\n<tr>\n<td>fibrinogen Sfax</td>\n<td><i>FGB</i>: c.679T&gt;C</td>\n<td>B\u03b2: Cys197Arg</td>\n<td>defective aggregation of fibrin</td>\n<td>post-surgical and <a href=\"/wiki/Postpartum\" class=\"mw-redirect\" title=\"Postpartum\">postpartum</a> bleeding, <a href=\"/wiki/Metrorrhagia\" class=\"mw-redirect\" title=\"Metrorrhagia\">metrorrhagia</a> during pregnancy\n</td></tr>\n<tr>\n<td>fibrinogen Vlissingen</td>\n<td><i>FGG</i>: c.1033_1038del</td>\n<td>\u03b3: delAsn319-Asp-320</td>\n<td>impaired secretion, defective calcium binding, defective polymerization</td>\n<td>venous thrombosis\n</td></tr>\n<tr>\n<td>fibrinogen Philadelphia</td>\n<td><i>FGG</i>: c.1210T&gt;C</td>\n<td>\u03b3: Ser378Pro</td>\n<td>impaired assembly of intracelllar fibrinogen, defective polymerization</td>\n<td>post-surgical, postpartum, and post-trauma bleeding\n</td></tr>\n<tr>\n<td>fibrinogen Freiburg</td>\n<td><i>FGG</i>: c.103C&gt;T</td>\n<td>\u03b3: Arg16Cys</td>\n<td>impaired assembly of intracelllar fibrinogen, defective polymerization</td>\n<td>recurrent venous and arterial thromboses\n</td></tr>\n<tr>\n<td>fibrinogen Leipzig II</td>\n<td><i>FGG</i>: c.323C&gt;G and <i>FGG</i> c.1129G&gt;A</td>\n<td>\u03b3: Ala108Gly and \u03bb: Gly377Ser</td>\n<td>impaired assembly of intracelllar fibrinogen, defective polymerization</td>\n<td>recurrent venous and arterial thromboses\n</td></tr>\n\n</tbody></table>\n<h2><span class=\"mw-headline\" id=\"Diagnosis\">Diagnosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hypodysfibrinogenemia&amp;action=edit&amp;section=4\" title=\"Edit section: Diagnosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Hypodysfibrinogenemia is usually diagnosed in individuals who: have a history of abnormal bleeding or thrombosis or are a <a href=\"/wiki/Consanguinity\" title=\"Consanguinity\">close blood relative</a> of such an individual. Initial laboratory findings include a decrease in serum fibrinogen mass levels as measured by <a href=\"/wiki/Immunoassay\" title=\"Immunoassay\">immunoassay</a> plus a reduction in inducible blood clot formation so that the ratio of functionally-detected fibrinogen mass (i.e. detected in induced clots) to immunoassay-detected fibrinogen mass is abnormally low, i.e. &lt;0.7. This contrast with individuals with congenital dysfibrinogenemia who exhibit normal levels of fibrinogen as measured by immunoassay but low functionally-detected to immunoassay-detected fibrinogen mass ratios, i.e. &lt;0.7. Where available, specialized laboratories can conduct studies to define the exact gene mutation(s) and fibrinogen abnormalities underlying the disorder.<sup id=\"cite_ref-pmid28211264_1-5\" class=\"reference\"><a href=\"#cite_note-pmid28211264-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid27019462_2-3\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid25816717_6-0\" class=\"reference\"><a href=\"#cite_note-pmid25816717-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Treatment\">Treatment</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hypodysfibrinogenemia&amp;action=edit&amp;section=5\" title=\"Edit section: Treatment\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Blood relatives of the <a href=\"/wiki/Proband\" title=\"Proband\">proband</a> case should be evaluated for the presence of hypodysfibrinogenemia. Individuals with the disorder need to be advised on its inheritance, complications, and preventative measures that can be taken to avoid bleeding and/or thrombosis. Since &gt;80% of individuals may develop bleeding or thrombosis complications of the disorder, asymptomatic individuals diagnosed with hydposyfibrinogenemia are best handled at a specialized center in order to benefit from multidisciplinary management.<sup id=\"cite_ref-pmid27019462_2-4\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup>\n</p><p>Measures to prevent and/or treat complications of hypodysfibrinogenemia should be tailored to the personal and family history of the individual by a specialized center. Individuals with a personal or family history of bleeding are considered to be of low risk of bleeding when their functional fibrinogen levels are &gt;1 gram/liter for major surgery, &gt;0.5 gram/liter for minor surgery, &gt;0.5 to 1-2 gram/liter for spontaneous bleeding (depending on its severity), &gt;0.5 to &gt; 1 gram/liter for the first two trimesters of pregnancy, and &gt;1 to &lt;2 gram/liter for the last trimester of pregnancy and postpartum period. Functional fibrinogen below these levels should be treated preferably with fibrinogen concentrate or if not available, fibrinogen-rich <a href=\"/wiki/Cryoprecipitate\" title=\"Cryoprecipitate\">cryoprecipitate</a> or plasma to attain low risk levels of functional fibrinogen.<sup id=\"cite_ref-pmid27019462_2-5\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup> <a href=\"/wiki/Antifibrinolytic\" title=\"Antifibrinolytic\">Antifibrinolytic</a> drugs such as <a href=\"/wiki/Tranexamic_acid\" title=\"Tranexamic acid\">tranexamic acid</a> or (\u03b5-aminocaproic acid) may be considered as an alternative preventative or therapeutic treatments in cases of minor surgery, dental extractions, mucosal bleeding, or other episodes of mild bleeding.<sup id=\"cite_ref-pmid27019462_2-6\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid27019463_4-3\" class=\"reference\"><a href=\"#cite_note-pmid27019463-4\">&#91;4&#93;</a></sup> In individuals with a personal or family history of thrombosis, should be considered for long-term <a href=\"/wiki/Anticoagulant\" title=\"Anticoagulant\">anticoagulation drugs</a> such as <a href=\"/wiki/Low_molecular_weight_heparin\" title=\"Low molecular weight heparin\">low molecular weight heparin</a>, <a href=\"/wiki/Warfarin\" title=\"Warfarin\">coumadin</a>, or <a href=\"/wiki/Rivaroxaban\" title=\"Rivaroxaban\">rivaroxaban</a>.<sup id=\"cite_ref-pmid27019462_2-7\" class=\"reference\"><a href=\"#cite_note-pmid27019462-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hypodysfibrinogenemia&amp;action=edit&amp;section=6\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-pmid28211264-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28211264_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28211264_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28211264_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28211264_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28211264_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid28211264_1-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Casini A, Brungs T, Lavenu-Bombled C, Vilar R, Neerman-Arbez M, de Moerloose P (2017). \"Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation\". <i>Journal of Thrombosis and Haemostasis</i>. <b>15</b> (5): 876\u2013888. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/jth.13655\">10.1111/jth.13655</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28211264\">28211264</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Thrombosis+and+Haemostasis&amp;rft.atitle=Genetics%2C+diagnosis+and+clinical+features+of+congenital+hypodysfibrinogenemia%3A+a+systematic+literature+review+and+report+of+a+novel+mutation&amp;rft.volume=15&amp;rft.issue=5&amp;rft.pages=876-888&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1111%2Fjth.13655&amp;rft_id=info%3Apmid%2F28211264&amp;rft.aulast=Casini&amp;rft.aufirst=A&amp;rft.au=Brungs%2C+T&amp;rft.au=Lavenu-Bombled%2C+C&amp;rft.au=Vilar%2C+R&amp;rft.au=Neerman-Arbez%2C+M&amp;rft.au=de+Moerloose%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHypodysfibrinogenemia\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27019462-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid27019462_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid27019462_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid27019462_2-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid27019462_2-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid27019462_2-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid27019462_2-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-pmid27019462_2-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-pmid27019462_2-7\"><sup><i><b>h</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Casini A, de Moerloose P, Neerman-Arbez M (2016). \"Clinical Features and Management of Congenital Fibrinogen Deficiencies\". <i>Seminars in Thrombosis and Hemostasis</i>. <b>42</b> (4): 366\u201374. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1055/s-0036-1571339\">10.1055/s-0036-1571339</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27019462\">27019462</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Thrombosis+and+Hemostasis&amp;rft.atitle=Clinical+Features+and+Management+of+Congenital+Fibrinogen+Deficiencies&amp;rft.volume=42&amp;rft.issue=4&amp;rft.pages=366-74&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1055%2Fs-0036-1571339&amp;rft_id=info%3Apmid%2F27019462&amp;rft.aulast=Casini&amp;rft.aufirst=A&amp;rft.au=de+Moerloose%2C+P&amp;rft.au=Neerman-Arbez%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHypodysfibrinogenemia\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28550239-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28550239_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28550239_3-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Caimi G, Canino B, Lo Presti R, Urso C, Hopps E (2017). \"Clinical conditions responsible for hyperviscosity and skin ulcers complications\". <i>Clinical Hemorheology and Microcirculation</i>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3233/CH-160218\">10.3233/CH-160218</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28550239\">28550239</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Hemorheology+and+Microcirculation&amp;rft.atitle=Clinical+conditions+responsible+for+hyperviscosity+and+skin+ulcers+complications&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.3233%2FCH-160218&amp;rft_id=info%3Apmid%2F28550239&amp;rft.aulast=Caimi&amp;rft.aufirst=G&amp;rft.au=Canino%2C+B&amp;rft.au=Lo+Presti%2C+R&amp;rft.au=Urso%2C+C&amp;rft.au=Hopps%2C+E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHypodysfibrinogenemia\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27019463-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid27019463_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid27019463_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid27019463_4-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid27019463_4-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Neerman-Arbez M, de Moerloose P, Casini A (2016). \"Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders\". <i>Seminars in Thrombosis and Hemostasis</i>. <b>42</b> (4): 356\u201365. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1055/s-0036-1571340\">10.1055/s-0036-1571340</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27019463\">27019463</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Thrombosis+and+Hemostasis&amp;rft.atitle=Laboratory+and+Genetic+Investigation+of+Mutations+Accounting+for+Congenital+Fibrinogen+Disorders&amp;rft.volume=42&amp;rft.issue=4&amp;rft.pages=356-65&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1055%2Fs-0036-1571340&amp;rft_id=info%3Apmid%2F27019463&amp;rft.aulast=Neerman-Arbez&amp;rft.aufirst=M&amp;rft.au=de+Moerloose%2C+P&amp;rft.au=Casini%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHypodysfibrinogenemia\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27784620-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid27784620_5-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Duval C, Ari\u00ebns RA (2017). \"Fibrinogen splice variation and cross-linking: Effects on fibrin structure/function and role of fibrinogen \u03b3' as thrombomobulin II\". <i>Matrix Biology</i>. 60-61: 8\u201315. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.matbio.2016.09.010\">10.1016/j.matbio.2016.09.010</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27784620\">27784620</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Matrix+Biology&amp;rft.atitle=Fibrinogen+splice+variation+and+cross-linking%3A+Effects+on+fibrin+structure%2Ffunction+and+role+of+fibrinogen+%CE%B3%27+as+thrombomobulin+II&amp;rft.volume=60-61&amp;rft.pages=8-15&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1016%2Fj.matbio.2016.09.010&amp;rft_id=info%3Apmid%2F27784620&amp;rft.aulast=Duval&amp;rft.aufirst=C&amp;rft.au=Ari%C3%ABns%2C+RA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHypodysfibrinogenemia\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid25816717-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid25816717_6-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Casini A, Neerman-Arbez M, Ari\u00ebns RA, de Moerloose P (2015). \"Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management\". <i>Journal of Thrombosis and Haemostasis</i>. <b>13</b> (6): 909\u201319. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/jth.12916\">10.1111/jth.12916</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25816717\">25816717</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Thrombosis+and+Haemostasis&amp;rft.atitle=Dysfibrinogenemia%3A+from+molecular+anomalies+to+clinical+manifestations+and+management&amp;rft.volume=13&amp;rft.issue=6&amp;rft.pages=909-19&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1111%2Fjth.12916&amp;rft_id=info%3Apmid%2F25816717&amp;rft.aulast=Casini&amp;rft.aufirst=A&amp;rft.au=Neerman-Arbez%2C+M&amp;rft.au=Ari%C3%ABns%2C+RA&amp;rft.au=de+Moerloose%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHypodysfibrinogenemia\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw2170\nCached time: 20180919120654\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.172 seconds\nReal time usage: 0.211 seconds\nPreprocessor visited node count: 758/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 13898/2097152 bytes\nTemplate argument size: 311/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 11700/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.085/10.000 seconds\nLua memory usage: 3.36 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  176.075      1 -total\n 49.94%   87.935      1 Template:Infobox_medical_condition_(new)\n 43.27%   76.186      1 Template:Reflist\n 42.92%   75.569      1 Template:Infobox\n 35.34%   62.231      6 Template:Cite_journal\n  2.13%    3.744      3 Template:Main_other\n  1.05%    1.848      1 Template:Template_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:55097960-0!canonical and timestamp 20180919120654 and revision id 856889086\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Infobox_medical_condition_(new)"},{"sortkey":"","hidden":"","*":"Medical_condition_not_in_Wikidata"},{"sortkey":"","*":"Coagulopathies"},{"sortkey":"","*":"Autosomal_dominant_disorders"},{"sortkey":"","*":"Rare_diseases"},{"sortkey":"","*":"Genetic_diseases_and_disorders"}],"links":[{"ns":0,"exists":"","*":"Abnormal uterine bleeding"},{"ns":0,"exists":"","*":"Adenine"},{"ns":0,"exists":"","*":"Amino acid"},{"ns":0,"exists":"","*":"Anticoagulant"},{"ns":0,"exists":"","*":"Antifibrinolytic"},{"ns":0,"exists":"","*":"Autosomal dominant"},{"ns":0,"exists":"","*":"Blood clotting"},{"ns":0,"exists":"","*":"Cerebral artery"},{"ns":0,"exists":"","*":"Cloned"},{"ns":0,"exists":"","*":"Compound heterozygosity"},{"ns":0,"exists":"","*":"Consanguinity"},{"ns":0,"exists":"","*":"Cryoprecipitate"},{"ns":0,"exists":"","*":"Cytosine"},{"ns":0,"exists":"","*":"Deep vein thrombosis"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Dysfibrinogenemia"},{"ns":0,"exists":"","*":"Fibrinogen"},{"ns":0,"exists":"","*":"Fibrinogen alpha chain"},{"ns":0,"exists":"","*":"Fibrinogen beta chain"},{"ns":0,"exists":"","*":"Frameshift mutation"},{"ns":0,"exists":"","*":"Glycoprotein"},{"ns":0,"exists":"","*":"Guanine"},{"ns":0,"exists":"","*":"Hepatic portal systems"},{"ns":0,"exists":"","*":"Heterozygous"},{"ns":0,"exists":"","*":"Homozygous"},{"ns":0,"exists":"","*":"Immunoassay"},{"ns":0,"exists":"","*":"List of fibrinogen disorders"},{"ns":0,"exists":"","*":"Locus (genetics)"},{"ns":0,"exists":"","*":"Low molecular weight heparin"},{"ns":0,"exists":"","*":"Menometrorrhagia"},{"ns":0,"exists":"","*":"Menorrhagia"},{"ns":0,"exists":"","*":"Menstruation"},{"ns":0,"exists":"","*":"Metrorrhagia"},{"ns":0,"exists":"","*":"Miscariage"},{"ns":0,"exists":"","*":"Missense mutation"},{"ns":0,"exists":"","*":"Missense mutations"},{"ns":0,"exists":"","*":"Nonsense mutation"},{"ns":0,"exists":"","*":"Partum"},{"ns":0,"exists":"","*":"Pathophysiology"},{"ns":0,"exists":"","*":"Penetrance"},{"ns":0,"exists":"","*":"Polymerization"},{"ns":0,"exists":"","*":"Postpartum"},{"ns":0,"exists":"","*":"Proband"},{"ns":0,"exists":"","*":"Protein trimer"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Pulmonary thrombosis"},{"ns":0,"exists":"","*":"Rivaroxaban"},{"ns":0,"exists":"","*":"Splice site mutation"},{"ns":0,"exists":"","*":"Stop codon"},{"ns":0,"exists":"","*":"Stroke"},{"ns":0,"exists":"","*":"Thymine"},{"ns":0,"exists":"","*":"Tranexamic acid"},{"ns":0,"exists":"","*":"Warfarin"}],"templates":[{"ns":10,"exists":"","*":"Template:Infobox medical condition (new)"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:String2"},{"ns":828,"exists":"","*":"Module:WikidataIB/sandbox"},{"ns":828,"exists":"","*":"Module:Complex date"},{"ns":828,"exists":"","*":"Module:I18n/complex date"},{"ns":828,"exists":"","*":"Module:Ordinal"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Roman"},{"ns":828,"exists":"","*":"Module:ISOdate"},{"ns":828,"exists":"","*":"Module:DateI18n"},{"ns":828,"exists":"","*":"Module:I18n/date"},{"ns":828,"exists":"","*":"Module:Calendar"},{"ns":828,"exists":"","*":"Module:I18n"},{"ns":828,"*":"Module:WikidataIB/i18n"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":[],"externallinks":["//doi.org/10.1111/jth.13655","//www.ncbi.nlm.nih.gov/pubmed/28211264","//doi.org/10.1055/s-0036-1571339","//www.ncbi.nlm.nih.gov/pubmed/27019462","//doi.org/10.3233/CH-160218","//www.ncbi.nlm.nih.gov/pubmed/28550239","//doi.org/10.1055/s-0036-1571340","//www.ncbi.nlm.nih.gov/pubmed/27019463","//doi.org/10.1016/j.matbio.2016.09.010","//www.ncbi.nlm.nih.gov/pubmed/27784620","//doi.org/10.1111/jth.12916","//www.ncbi.nlm.nih.gov/pubmed/25816717"],"sections":[{"toclevel":1,"level":"2","line":"Presentation","number":"1","index":"1","fromtitle":"Hypodysfibrinogenemia","byteoffset":3353,"anchor":"Presentation"},{"toclevel":1,"level":"2","line":"Fibrinogen","number":"2","index":"2","fromtitle":"Hypodysfibrinogenemia","byteoffset":4495,"anchor":"Fibrinogen"},{"toclevel":1,"level":"2","line":"Pathophysiology","number":"3","index":"3","fromtitle":"Hypodysfibrinogenemia","byteoffset":5911,"anchor":"Pathophysiology"},{"toclevel":1,"level":"2","line":"Diagnosis","number":"4","index":"4","fromtitle":"Hypodysfibrinogenemia","byteoffset":10550,"anchor":"Diagnosis"},{"toclevel":1,"level":"2","line":"Treatment","number":"5","index":"5","fromtitle":"Hypodysfibrinogenemia","byteoffset":11869,"anchor":"Treatment"},{"toclevel":1,"level":"2","line":"References","number":"6","index":"6","fromtitle":"Hypodysfibrinogenemia","byteoffset":13842,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Hypodysfibrinogenemia","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q42417349"}]}}